Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient

Novel carbapenem-β-lactamase inhibitor combination, imipenem/relebactam (IMI-REL), has been recently approved for treatment of infections with limited or no alternative treatment options. In this study, we described the emergence of the IMI-REL-resistance in a KPC-producing Klebsiella pneumoniae (KP...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaibani, Paolo, Bussini, Linda, Amadesi, Stefano, Bartoletti, Michele, Bovo, Federica, Lazzarotto, Tiziana, Viale, Pierluigi, Ambretti, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025179/
https://www.ncbi.nlm.nih.gov/pubmed/35456827
http://dx.doi.org/10.3390/microorganisms10040778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025179/
https://www.ncbi.nlm.nih.gov/pubmed/35456827
http://dx.doi.org/10.3390/microorganisms10040778

Ejemplares similares